New Advances in Lymphoma, AML, MDS, and CLL Treatments

ONO PHARMA’s tirabrutinib showed a 67% response rate in rare brain lymphoma, supporting potential U.S. approval. Merck’s zilovertamab vedotin delivered 56% response in DLBCL, while Kite’s Yescarta proved safe for outpatient use. Zanubrutinib maintained strong five-year outcomes in high-risk CLL/SLL. InnoCare launched a mesutoclax trial in MDS, and Estrella advanced its CD19 T-cell therapy in CNS lymphoma. Iksuda began trials for IKS03 ADC, and Auron dosed its first patient in a study of AUTX-703 for AML/MDS, targeting cancer epigenetics.

Видео New Advances in Lymphoma, AML, MDS, and CLL Treatments канала LucidQuest